Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6952-6957

  Pal, S ^a   Datta, K ^a   Mukhopadhyay, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN KINASE P60; PROTEIN P53; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NORTHERN BLOTTING; ONCOGENE SRC; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL HYPOXIA; DOWN-REGULATION; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHOKINES; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; SRC-FAMILY KINASES; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035884402     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Tumor angiogenesis: Therapeutic implications
2. Fighting cancer by attacking its blood supply
3. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
4. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix
5. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
6. Vascular endothelial growth factor is a secreted angiogenic mitogen
7. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
8. Implications of the new biology for therapy in breast cancer
9. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
10. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
11. Angiogenic molecules and mechanisms in breast cancer
12. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
13. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
14. The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity
15. Mutant ras oncogenes upregulate VEGF-VPF expression: Implications for induction and inhibition of tumor angiogenesis
16. Role of PKC z in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression
17. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
18. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
19. p53, the cellular gatekeeper for growth and division
20. The complexity of p53 modulation: Emerging patterns from divergent signals
21. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
22. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
23. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
24. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
25. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo
26. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas
27. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity
28. Involvement of pp60c-src with two major signaling pathways in human breast cancer
29. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice
30. Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation
31. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis
32. Activity of pp60c-src protein kinase in human breast cancer
33. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
34. Activation of Src in human breast tumor cell lines: Elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530
35. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
36. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells
37. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction
38. The p53 proto-oncogene can act as a suppressor of transformation
39. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53
40. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
41. Cancer genetics
42. Regulatory pathways in tumor growth and invasion
43. p53 tumour suppressor gene and germ cell neoplasia
44. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
45. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene
46. p53 inhibits hypoxia-inducible factor-stimulated transcription
47. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice
48. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model
49. Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line
50. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2
51. Increase of protein tyrosine phosphorylation in ray retina after ischemia-reperfusion injury
52. Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells